-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TQvo3yR0DBoJEACuKyecm6qY7G/NQ79TncD3LeZzlkYn3IctYSyRl/wY/teMUBcd YHoUiZw2Z5nDgrWFVzlykA== 0000038074-08-000027.txt : 20081211 0000038074-08-000027.hdr.sgml : 20081211 20081211143832 ACCESSION NUMBER: 0000038074-08-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20080930 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20081211 DATE AS OF CHANGE: 20081211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FOREST LABORATORIES INC CENTRAL INDEX KEY: 0000038074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 111798614 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05438 FILM NUMBER: 081243254 BUSINESS ADDRESS: STREET 1: 909 THIRD AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212)421-7850 MAIL ADDRESS: STREET 1: 909 THIRD AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 forest8ksept08xbrl.htm FOREST 8-K SEPTEMBER 30, 2008 XBRL forest8ksept08xbrl.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
__________________________________________

Pursuant to Section 13 or 15 (d) of
The Securities Exchange Act of 1934

December 11, 2008
Date of report (date of earliest event reported)

    FOREST LABORATORIES, INC.    
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
1-5438
(Commission
   File Number)
11-1798614
(I.R.S. Employer
Identification Number)
     
909 Third Avenue
New York, New York
(Address of principal executive offices)
  
10022-4731
(Zip code)

(212) 421-7850
(Registrant's telephone number, including area code)

                                                None                                             
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01   OTHER EVENTS

Forest Laboratories, Inc. (the “Company”) is participating in the Securities and Exchange Commission’s XBRL (eXtensible Business Reporting Language) voluntary filing program.  In connection with this program, the Company has attached as Exhibit 100 to this Current Report on Form 8-K the following financial information from its Quarterly Report on Form 10-Q for the Quarter ended September 30, 2008, filed with the Securities and Exchange Commission on November 10, 2008, formatted in XBRL: (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements.

Users of this data are advised pursuant to Rule 401 of Regulation S-T that the financial information contained in the XBRL documents is unaudited and these are not the official publicly filed financial statements of the Company.  The purpose of submitting these XBRL formatted documents is to test the related format and technology and, as a result, investors should continue to rely on the official filed version of the furnished documents and not rely on the information in this Current Report on Form 8-K, including the Exhibit 100, in making investment decisions.

In accordance with Rule 402 of Regulation S-T, the information in this Current Report on Form 8-K, including Exhibit 100, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific references in such filing.

Item 9.01   Financial Statements and Exhibits.

(d)  Exhibits

 The following exhibits are furnished herewith:

     
Exhibit No.
  
Exhibit Description
 
100
  
The following financial statements from Forest Laboratories, Inc’s Quarterly Report on Form 10-Q for the six months ended September 30, 2008, filed on November 10, 2008, formatted in XBRL (eXtensive Business Reporting Language): (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements.




SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date:  December 11, 2008



Forest Laboratories, Inc.
(Registrant)


/s/ Francis I. Perier, Jr.                      
Francis I. Perier, Jr.
Senior Vice President - Finance and
Chief Financial Officer





Exhibit Index

Exhibit No.
Description
   
EX-100.INS
XBRL Instance Document
EX-100.SCH
XBRL Taxonomy Extension Schema Document
EX-100.PRE
XBRL Taxonomy Presentation Linkbase Document
EX-100.LAB
XBRL Taxonomy Label Linkbase Document
EX-100.CAL
XBRL Taxonomy Calculation Linkbase Document
   
   




EX-100.INS 2 frx-20080930.xml XBRL INSTANCE DOCUMENT 0000038074 2008-09-30 Unaudited 0000038074 2008-03-31 0000038074 2007-06-30 2007-09-30 Unaudited 0000038074 2008-06-30 2008-09-30 Unaudited 0000038074 2008-04-01 2008-09-30 Unaudited 0000038074 2007-04-01 2007-09-30 Unaudited 0000038074 2008-04-01 Unaudited 0000038074 2007-04-01 Unaudited 0000038074 2007-09-30 Unaudited iso4217:USD xbrli:shares 236000 5071000 70801000 52547000 142318000 128183000 992506000 918960000 1959350000 1847234000 219875000 226095000 10. Termination of Co-Promotion Agreement (In Thousands): During the quarter ended June 30, 2008, the Company and its licensing partner Daiichi Sankyo, terminated their co-promotion agreement for Azor. As a result of terminating the agreement, the Company recorded a one-time charge of $44,100 to selling, general and administrative expense which was composed of a termination fee of approximately $26,600 and $17,500 related to the unamortized portion of the initial upfront payment. -151025000 26977000 35895000 21588000 22754000 23075000 314887000 277791000 629324000 621589000 -3739541000 -3407082000 6098499000 5611493000 72695000 223720000 423023000 445987000 1069842000 833052000 833052000 563663000 959763000 -1247144000 -1244988000 549362000 601069000 0.80 0.71 1.59 1.54 2. Accounts Receivable: Accounts receivable, net, consists of the following: (In thousands) September 30, 2008 March 31, 2008 (Unaudited) ------------------ ------------------ Trade $ 326,202 $ 377,779 Other 96,821 68,208 ------------------ ------------------ $ 423,023 $ 445,987 ================== ================== 236790000 396100000 22964000 -40287000 -630000 -137000 304346 315510 305687 317534 925570000 842337000 1819315000 1684953000 3059173000 2907504000 8. Long-Term Debt: On December 7, 2007, the Company established a $500 million revolving credit facility for the purpose of providing additional financial liquidity for the financing of business development and corporate strategic initiatives. The facility can be increased up to $750 million based upon agreement with the participating lenders and expires on December 7, 2012. As of November 7, 2008, the Company has not drawn any funds from the available credit. The utilization of the revolving credit facility is subject to the adherence to certain financial covenants such as leverage and interest coverage ratios. 1309441000 1295045000 47210000 50313000 101363000 103690000 42156000 42142000 820025000 943972000 43057000 32266000 -10000 8382000 0.80 0.71 1.59 1.55 532000 1378000 1248000 6921000 610933000 610825000 538238000 387105000 567959000 604201000 75574000 33260000 9. Income Taxes (In Thousands): The Company files income tax returns in the United States and certain foreign jurisdictions including Ireland. The Company's income tax returns for fiscal years prior to 1999 in most jurisdictions and prior to 2002 in Ireland are no longer subject to review as such fiscal years are generally closed. Tax authorities in various jurisdictions are in the process of reviewing the Company's income tax returns for various post-1999 fiscal years, including the Internal Revenue Service (or IRS), which has recently concluded its examination of the Company's U.S. federal income tax returns for fiscal years 2002 and 2003. In connection with that examination, in July 2007, the IRS issued a notice of proposed adjustment primarily relating to the Company's intercompany transfer pricing methodology. On November 5, 2007, the IRS issued a Revenue Agent Report which seeks to assess approximately $207 million of additional U.S. corporation income tax relating to the examination period, excluding interest and penalties. The Company continues to disagree with the IRS position and adjustment because it believes that it is inconsistent with applicable tax laws and the Company intends to defend its position vigorously. In accordance with the Company's taxpayer appeals rights, a formal written protest of the proposed adjustment has been filed with the IRS and the matter is in administrative appeals. While the resolution of this issue may result in tax liabilities that are greater or less than the reserves established, Management believes that the ultimate resolution will not have a material effect on the Company's financial position or liquidity. If the IRS prevails in a position that increases the U.S. income tax liability in excess of established reserves, it is likely that the IRS could make similar claims for years subsequent to fiscal 2003 which could be material. However, at this time Management believes that it is unlikely that the ultimate outcome will be determined within the next 12 months. The Company's continuing practice is to recognize net interest related to income tax matters in income tax expense. As of September 30, 2008, the Company had accrued an additional $3,223 in interest for a total of $23,162 related to the resolution of various income tax matters. The Company's effective tax rate was 22.5% and 22.6% for the three and six-month periods ended September 30, 2008, as compared to 18.9% and 20.6% for the same periods last year. The increase resulted primarily from the net impact of one-time discrete tax adjustments related principally to stock-based compensation in prior years offset for the most part by the termination of our co-promotion agreement for Azor(TM) and other tax matters including the expiration of the U.S. Federal research and experimentation tax credit on December 31, 2007, which was re-enacted on October 3, 2008 and will have a favorable impact on the Company's third and fourth quarter effective tax rates. Effective tax rates may be affected by ongoing tax audits. 3378000 24856000 205001000 189992000 402342000 376232000 221514000 198410000 1. Basis of Presentation (In Thousands): The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or GAAP) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of Management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended September 30, 2008 are not necessarily indicative of the results that may be expected for the year ending March 31, 2009. For further information refer to the consolidated financial statements and footnotes thereto incorporated by reference in the Company's Annual Report on Form 10-K for the year ended March 31, 2008. -25696000 -13161000 1681000 1671000 -332459000 -274804000 23104000 24330000 5927000 -5304000 0 0 60065000 59778000 491248000 527787000 6. Stock-Based Compensation (In Thousands): In August 2007 the stockholders of the Company voted to adopt the 2007 Equity Incentive Plan (or the 2007 Plan) which replaces and supersedes all prior stock option plans. Under the 2007 Plan, 13,950 shares were authorized to be issued to employees of the Company and its subsidiaries at prices not less than the fair market value of the common stock at the date of grant. The 2007 Plan provides for the granting of incentive and nonqualified stock options, restricted stock, stock appreciation rights and stock equivalent units. These awards generally vest in three to five years. Stock option grants may be exercisable for up to ten years from the date of issuance. As of September 30, 2008, 9,288 shares were available for grant. Compensation expense of $9,667 ($8,227 net of tax) and $20,254 ($17,044 net of tax) was recorded for the three and six-month periods ended September 30, 2008, respectively. For the three and six-month periods ended September 30, 2007, compensation expense of $9,402 ($8,104 net of tax) and $20,078 ($16,996 net of tax) was recorded. This expense was charged to cost of sales, selling, general and administrative and research and development expense, as appropriate. The weighted average number of diluted common shares outstanding is reduced by the treasury stock method which, in accordance with the provisions of Statement of Financial Accounting Standards No. 123(R), "Share-Based Payment" (or SFAS 123R) takes into consideration the compensation cost attributed to future services not yet recognized. 244086000 225244000 487006000 493406000 4698101000 4525367000 584470000 567331000 4. Fair Value Measurements: In the first quarter of fiscal 2009, the Company adopted SFAS No. 157 (or SFAS 157), "Fair Value Measurements." This pronouncement defines fair value, establishes a framework for measuring fair value under GAAP and requires expanded disclosures about fair value measurements. SFAS 157 does not require any new fair value measurements, but rather generally applies to other accounting pronouncements that require or permit fair value measurements. SFAS 157 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and defines fair value as the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. SFAS 157 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). These valuation techniques are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. SFAS 157 utilizes a fair value hierarchy that prioritizes inputs to fair value measurement techniques into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets. Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3: Unobservable inputs that reflect the reporting entity's own assumptions. The Financial Accounting Standards Board (or FASB) issued FSP 157-2 which delayed the effective date of SFAS 157 for all non-financial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, until the beginning of fiscal 2010. In October 2008, the FASB issued FSP 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active." FSP 157-3 clarifies the application of SFAS 157 in a market that is not active and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for that financial asset is not active. FSP 157-3 is effective upon issuance, including prior periods for which financial statements have not been issued. The Company's financial assets adjusted to fair value at September 30, 2008 are its commercial paper investments included in cash and cash equivalents, money market accounts, municipal bonds and notes, variable rate demand notes, floating rate notes and auction rate securities. These assets are subject to the measurement and disclosure requirements of SFAS 157. The Company adjusts the value of these instruments to fair value each reporting period. No adjustment to retained earnings resulted from the adoption of SFAS 157. The following table presents the level within the fair value hierarchy at which the Company's financial assets are carried at fair value and measured on a recurring basis: (In thousands) Quoted Prices Significant Other Fair Value at in Active Markets Observable Market September 30, for Identical Assets Inputs Description 2008 (Level 1) (Level 2) - ----------- ------------- -------------------- ----------------- Money market accounts $ 830,263 $ 830,263 Municipal bonds and notes 191,965 $ 191,965 Commercial paper 775,765 383,709 392,056 Variable rate demand notes 214,659 214,659 Floating rate notes 437,271 265,387 171,884 Auction rate securities 38,795 38,795 Money market accounts are included in cash and cash equivalents on the accompanying balance sheets and are classified as Level 1 assets. Certain commercial paper and floating rate note investments are also classified as Level 1 assets because they consist of publicly traded securities which are priced and actively traded on a daily basis. The Company holds investments in auction rate securities (or ARS) amounting to $38,795 (with underlying maturities from 23.3 to 33.7 years) of which $23,500 are collateralized by student loans. Substantially all such collateral in the aggregate is guaranteed by the U.S. government under the Federal Family Education Loan Program. The balance of the ARS investments of $15,295 are issued by local municipal governments. Liquidity for these securities was normally dependent on an auction process that resets the applicable interest rate at pre-determined intervals, ranging from 7 to 35 days. Beginning in February 2008, the auctions for the ARS held by the Company and others were unsuccessful, requiring the Company to continue to hold them beyond their typical auction reset dates. Auctions fail when there is insufficient demand. However, this does not represent a default by the issuer of the security. Upon an auction's failure, the interest rates reset based on a formula contained in the security. The rate is generally equal to or higher than the current market rate for similar securities. The securities will continue to accrue interest and be auctioned until one of the following occurs: the auction succeeds; the issuer calls the securities; or the securities mature. The Company classifies the ARS as non-current assets held for sale under the heading "Marketable securities" in the Company's balance sheets and values them at purchase price free from impairment. The Company determines the fair value of these ARS instruments based on Level 2 inputs in the SFAS 157 fair value hierarchy. Level 2 fair value determinations are derived from directly or indirectly observable market based information. Certain of the Company's commercial paper and floating rate notes and all of the Company's variable rate notes and municipal bonds and notes are based on Level 2 inputs in the SFAS 157 fair value hierarchy. 3. Inventories: Inventories, net of reserves for obsolescence, consist of the following: (In thousands) September 30, 2008 March 31, 2008 (Unaudited) ------------------ -------------- Raw materials $ 178,108 $ 234,288 Work in process 1,711 1,360 Finished goods 271,015 189,490 ------------------ -------------- $ 450,834 $ 425,138 ================== ============== 450834000 425138000 11. Contingencies - Securities Litigation (In Thousands): The Company and certain of its officers have been named as defendants in consolidated securities cases brought in the U.S. District Court for the Southern District of New York on behalf of a class of all purchasers of the Company's securities from August 15, 2002 through July 2, 2004 and consolidated under the caption "In re Forest Laboratories, Inc. Securities Litigation." On September 22, 2008, the Company entered into a Memorandum of Understanding (or MOU) setting forth an agreement in principle to settle all claims against all defendants for $65,000. While the Company expects such settlement to be fully funded by insurance and is engaged in discussions with the carriers concerning their liability for the payment, during the September 2008 quarter the Company recorded a reserve of $25,000 in connection with the MOU. 5. Net Income Per Share (In Thousands): A reconciliation of shares used in calculating basic and diluted net income per share follows: Three Months Ended Six Months Ended September 30, September 30, ------------------------ ------------------------- 2008 2007 2008 2007 ----------- ----------- ------------ ----------- Basic 304,346 315,510 305,687 317,534 Effect of assumed conversion of employee stock options and restricted stock 1,159 1,342 1,014 1,841 ----------- ----------- ------------ ----------- Diluted 305,505 316,852 306,701 319,375 =========== =========== ============ =========== Options to purchase approximately 14,996 shares of common stock at exercise prices ranging from $34.12 to $76.66 per share and options to purchase approximately 14,974 shares of common stock at exercise prices ranging from $34.12 to $76.66 per share that were outstanding during a portion of the three and six-month periods ended September 30, 2008, respectively, were not included in the computation of diluted net income per share because they were anti-dilutive. These options expire through 2018. Options to purchase approximately 12,238 shares of common stock at exercise prices ranging from $36.50 to $76.66 per share and options to purchase approximately 10,149 shares of common stock at exercise prices ranging from $36.50 to $76.66 per share that were outstanding during a portion of the three and six-month periods ended September 30, 2007, respectively, were not included in the computation of diluted net income per share because they were anti-dilutive. These options expire through 2017. 135342000 104082000 146357000 170738000 258469000 307646000 3864845000 3715317000 1458025000 1434172000 7. Business Segment Information: The Company operates in only one segment. Below is a breakdown of net sales by therapeutic class: Three Months Ended Six Months Ended (In thousands) September 30, September 30, --------------------------- ------------------------------- 2008 2007 2008 2007 ------------ ------------ ------------- -------------- Central nervous system $ 833,112 $ 756,969 $ 1,643,432 $ 1,504,477 Cardiovascular 19,593 6,849 29,408 15,268 Other 72,865 78,519 146,475 165,208 ------------ ------------ ------------- -------------- $ 925,570 $ 842,337 $ 1,819,315 $ 1,684,953 ============ ============ ============= ============== 151133000 60751000 -27964000 6498000 -28886000 8477000 677619000 641169000 1330026000 1225645000 345694000 350037000 -26784000 7642000 -42314000 -18629000 326261000 280439000 669215000 541767000 14965000 14965000 238776000 217294000 -19240000 -17791000 222323000 199225000 725275000 663625000 20254000 20078000 19194000 24932000 37424000 51670000 4698101000 4525367000 5706000 34592000 -328845000 -244877000 216122000 231742000 458120000 501883000 305505 316852 306701 319375 809000 815000 EX-100.SCH 3 frx-20080930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 124100 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink 104000 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink 148400 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink 152200 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink Notes to Condensed Consolidated Financial Statements link:presentationLink EX-100.PRE 4 frx-20080930_pre.xml XBRL TAXONOMY PRESENTATION LINKBASE DOCUMENT EX-100.LAB 5 frx-20080930_lab.xml XBRL TAXONOMY LABEL LINKBASE DOCUMENT Accounts payable Accounts receivable, net Accrued expenses Accumulated other comprehensive income Less: accumulated depreciation Additional paid-in capital Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Accounts receivable, net Income tax liabilities Inventories, net Other current assets Accounts payable Accrued expenses Stock-Based Compensation [Text Block] Contingencies - Securities Litigation [Text Block] Common stock, $.10 par; shares authorized 1,000,000; issued 421,562 shares in September and 421,421 shares in March Comprehensive income Cost of sales Total current liabilities Deferred income tax expense (benefit) Termination of Co-Promotion Agreement [Text Block] Net income per common share - diluted Effect of exchange rate changes on cash Stock-based compensation expense Income taxes payable Other assets License agreements, product rights and other intangibles, net Inventories, net Total liabilities and stockholders' equity Marketable securities Marketable securities Net cash used in financing activities Net cash provided by investing activities Net cash provided by operating activities Net income Increase in cash and cash equivalents Total other assets Total noncurrent liabilities Total revenue Basis of Presentation [Text Block] Other comprehensive (loss) income Unrealized holding (loss) gain arising during the period, net of tax Other current assets Other income Redemption of marketable securities Net proceeds from common stock options exercised by employees under stock option plans Property, plant and equipment, gross Property, plant and equipment, net Purchase of license agreements, product rights and other intangibles Purchase of marketable securities Purchase of property, plant and equipment Purchase of treasury stock Retained earnings Contract revenue Net sales Inventories [Text Block] Business Segment Information [Text Block] Selling, general and administrative Income taxes Total current assets Weighted average number of common shares outstanding - diluted Weighted average number of common shares outstanding - basic Research and development Total assets Accounts Receivable [Text Block] Interest income Deferred income taxes Stock-Based Compensation [Text Block] Deferred income taxes Deferred income taxes Machinery, equipment and other Fair Value Measurements [Text Block] Treasury stock, at cost (120,182 shares in September and 110,014 shares in March) Net income per common share - basic Other assets Total operating income Income before income tax expense Foreign currency translation gains (losses) Total stockholders' equity Income tax expense Series preferred stock, $1.00 par; shares authorized 1,000; no shares issued or outstanding Tax benefit realized from the exercise of stock options by employees Foreign currency transaction gain Income tax liabilities Land and buildings Carrying amount as of the balance sheet date of real estate held for productive use. This excludes land held for sale. Carrying amount as of the balance sheet date of long-lived, depreciable assets that include building structures held for productive use including any addition, improvement, or renovation to the structure, such as interior masonry, interior flooring, electrical, and plumbing. Amortization and impairments Supplemental Disclosures of Cash Flow Information [Abstract] Net Income Per Share [Text Block] This element may be used to capture the complete disclosure pertaining to an entity's basic and diluted earnings per share Notes to Consolidated Financial Statements Termination of Co-Promotion Agreement [Text Block] Description of termination of co-promotion agreement in which the entity was a participant, including a) information about the nature and purpose of such agreement; b) its rights and obligations under thereunder; c) the accounting policy for co-promotion agreement ; and d) the income statement classification and amounts attributable to transactions arising from the co-promotion agreement between participants. EX-100.CAL 6 frx-20080930_cal.xml XBRL TAXONOMY CALCULATION LINKBASE DOCUMENT -----END PRIVACY-ENHANCED MESSAGE-----